AstraZeneca homes in on new HQ and research site in Cambridge

AstraZeneca's new CEO has zeroed in on a site for its new headquarters and R&D center in the U.K. Over the next three years the pharma company ($AZN) plans to build a $500 million complex on an 11-acre site at the Cambridge BioMedical Campus. The new campus will house its U.K. operations for biologics and small molecule research as well as the corporate staff, now operating in London. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.